UCB S.A. (UCBJF)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Strong 5/5 metrics rated Sunny
What does UCB S.A. do?
UCB SA, a biopharmaceutical 💉 company headquartered in Brussels 🇧🇪, develops products and solutions for people with neurology and immunology diseases. With a wide range of offerings including Cimzia for inflammatory diseases and Vimpat, Keppra, and Briviact for epilepsy, UCB SA is committed to improving the lives of those affected. They also have collaboration agreements with big names like Amgen, Biogen, and Novartis. Let's keep our fingers crossed 🤞 for their exciting developments in treating Alzheimer's and Parkinson's disease! 🧠💪🕺.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ☀️ Strong | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $248.60 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Based on 5-year performance trends, UCB S.A. has historically delivered strong returns. Sign up free for full valuation analysis including P/E, DCF estimates, and Stockbruh's plain-English take on whether this stock looks cheap or expensive right now.
How the business works
UCB SA, a biopharmaceutical 💉 company headquartered in Brussels 🇧🇪, develops products and solutions for people with neurology and immunology diseases. With a wide range of offerings including Cimzia for inflammatory diseases and Vimpat, Keppra, and Briviact for epilepsy, UCB SA is committed to improving the lives of those affected. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — UCB S.A. appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.